Search Results - "Blankenstein, Stephanie"

Adjuvant systemic therapy in high-risk melanoma by Blankenstein, Stephanie A, van Akkooi, Alexander C J

“…In resected high-risk melanoma (stage IIB/C-III) the risk of locoregional and/or distant recurrence is substantial and so far adjuvant therapies have been…”
Get full text

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance by Boshuizen, Julia, Vredevoogd, David W., Krijgsman, Oscar, Ligtenberg, Maarten A., Blankenstein, Stephanie, de Bruijn, Beaunelle, Frederick, Dennie T., Kenski, Juliana C. N., Parren, Mara, Brüggemann, Marieke, Madu, Max F., Rozeman, Elisa A., Song, Ji-Ying, Horlings, Hugo M., Blank, Christian U., van Akkooi, Alexander C. J., Flaherty, Keith T., Boland, Genevieve M., Peeper, Daniel S.

“…Melanomas can switch to a dedifferentiated cell state upon exposure to cytotoxic T cells. However, it is unclear whether such tumor cells pre-exist in patients…”
Get full text

Postoperative radiotherapy in stage I–III Merkel cell carcinoma by Levy, Sonja, Blankenstein, Stephanie A., Grünhagen, Dirk Jan, Jalving, Mathilde, Hamming-Vrieze, Olga, Been, Lukas B., Tans, Lisa, van Akkooi, Alexander C.J., Tesselaar, Margot E.T.

“…•PORT is associated with less recurrences in stage III MCC.•PORT does not improve MCC-related survival.•OS benefit of PORT in MCC patients is likely associated…”
Get full text

Comment on “Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial” by Stahlie, Emma H. A., Blankenstein, Stephanie A., van Houdt, Winan J., Wouters, Michel W. J. M., van Akkooi, Alexander C. J.

Get full text

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance by Boshuizen, Julia, Vredevoogd, David W., Krijgsman, Oscar, Ligtenberg, Maarten A., Blankenstein, Stephanie, de Bruijn, Beaunelle, Frederick, Dennie T., Kenski, Juliana C. N., Parren, Mara, Brüggemann, Marieke, Madu, Max F., Rozeman, Elisa A., Song, Ji-Ying, Horlings, Hugo M., Blank, Christian U., van Akkooi, Alexander C. J., Flaherty, Keith T., Boland, Genevieve M., Peeper, Daniel S.

Get full text

Surgery for Metastatic Melanoma: an Evolving Concept by Testori, Alessandro A. E., Blankenstein, Stephanie A., van Akkooi, Alexander C. J.

“…Purpose of Review This review describes the evolving role of surgery in stage III and IV melanoma. Recent Findings Surgery has been the first option to cure…”
Get full text

Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma by Versluis, Judith M, Blankenstein, Stephanie A, Dimitriadis, Petros, Wilmott, James S, Elens, Robert, Blokx, Willeke A M, van Houdt, Winan, Menzies, Alexander Maxwell, Schrage, Yvonne M, Wouters, Michel W J M, Sanders, Joyce, Broeks, Annegien, Scolyer, Richard A, Suijkerbuijk, Karijn P M, Long, Georgina V, Akkooi, Alexander C J van, Blank, Christian U

“…BackgroundA substantial proportion of patients with macroscopic stage III melanoma do not benefit sufficiently from adjuvant anti-PD-1 therapy, as they either…”
Get full text

18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence? by van der Hiel, Bernies, Blankenstein, Stephanie A., Aalbersberg, Else A., Wondergem, Maurits, Stokkel, Marcel P.M., van de Wiel, Bart A., Klop, W. Martin C., van Akkooi, Alexander C.J., Haanen, John B.

“…The aim of this study was to investigate whether 18F-FDG PET/CT can predict histopathological response or recurrence in BRAF-mutated unresectable locally…”
Get full text

Primary Melanoma: from History to Actual Debates by Testori, Alessandro A. E., Blankenstein, Stephanie A., van Akkooi, Alexander C. J.

“…Purpose of Review This review describes the long scientific background followed to design guidelines and everyday clinical practice applied to melanoma…”
Get full text

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma by Stahlie, Emma H. A., Blankenstein, Stephanie A., Houdt, Winan J., Wouters, Michel W. J. M., Akkooi, Alexander C. J.

Get full text

Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial by Blankenstein, Stéphanie A., Rohaan, Maartje W., Klop, Willem Martin C., van der Hiel, Bernies, van de Wiel, Bart A., Lahaye, Max J., Adriaansz, Sandra, Sikorska, Karolina, van Tinteren, Harm, Sari, Aysegül, Grijpink-Ongering, Lindsay G., van Houdt, Winan J., Wouters, Michel W. J. M., Blank, Christian U., Wilgenhof, Sofie, van Thienen, Johannes V., van Akkooi, Alexander C. J., Haanen, John B. A. G.

“…To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical…”
Get full text

Mental Health Correlates of Healthy Lifestyle Attitudes, Beliefs, Choices, and Behaviors in Overweight Adolescents by Melnyk, Bernadette Mazurek, Small, Leigh, Morrison-Beedy, Dianne, Strasser, Anne, Spath, Lisa, Kreipe, Richard, Crean, Hugh, Jacobson, Diana, Van Blankenstein, Stephanie

“…A tripling in the number of overweight adolescents has occurred during the past two decades, with type 2 diabetes reaching epidemic proportions. Although…”
Get full text

Postoperative radiotherapy in stage I-III Merkel cell carcinoma by Levy, Sonja, Blankenstein, Stephanie A., Grünhagen, Dirk Jan, Jalving, Mathilde, Hamming-Vrieze, Olga, Been, Lukas B., Tans, Lisa, van Akkooi, Alexander C.J., Tesselaar, Margot E.T.

Get full text

Postoperative radiotherapy in Merkel cell carcinoma (MCC) by Levy, Sonja, Blankenstein, Stephanie, Grunhagen, Dirk J., Jalving, Mathilde, Hamming-Vrieze, Olga, Been, Lukas B., Tans, Lisa, Van Akkooi, Alexander Christopher Jonathan, Tesselaar, Margot Et

“…Abstract only 9575 Background: MCC is a rare and aggressive neuroendocrine malignancy of the skin. Postoperative radiotherapy (PORT) is recommended by current…”
Get full text

The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy by Versluis, Judith M., Blankenstein, Stephanie, Dimitriadis, Petros, Sanders, Joyce, Hoefakker, Willem, Broeks, Annegien, van Houdt, Winan J., Schrage, Yvonne M., Wouters, Michel W.J.M., Van Akkooi, Alexander Christopher Jonathan, Blank, Christian U.

“…Abstract only 9579 Background: Recently, trials have shown the benefit of adjuvant aPD-1 therapy in macroscopic stage III melanoma patients. This treatment has…”
Get full text

18 F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients : Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence? by van der Hiel, Bernies, Blankenstein, Stephanie A., Aalbersberg, Else A., Wondergem, Maurits, Stokkel, Marcel P.M., van de Wiel, Bart A., Klop, W. Martin C., van Akkooi, Alexander C.J., Haanen, John B.

Get full text

Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial by Blankenstein, Stephanie A., Rohaan, Maartje W., Klop, W. Martin. C., Van Der Hiel, Bernies, Van De Wiel, Bart A., Peeper, Daniel S., Haanen, John B. A. G., Van Akkooi, Alexander Christopher Jonathan

“…Abstract only 9587 Background: The aim of this study is to evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib and trametinib…”
Get full text

Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy by Blankenstein, Stephanie, Aarts, Maureen J.B., van den Berkmortel, Franchette, Boers-Sonderen, Marye, van den Eertwegh, Alfonsus Johannes Maria, Franken, Margreet G., de Groot, Jan Willem, Haanen, John B. A. G., Hospers, Geke, Kapiteijn, Ellen, Piersma, Djura, Van Rijn, Rozemarijn, Suijkerbuijk, Karijn, ten Tije, Albert J., Van Der Veldt, Astrid Aplonia Maria, Vreugdenhil, Gerard, Wouters, Michel W.J.M., Van Akkooi, Alexander Christopher Jonathan

“…Abstract only 10032 Background: Over the past decade opportunities for surgical treatment in metastatic melanoma patients have re-emerged due to the…”
Get full text

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? by Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., van Akkooi, Alexander C. J.

“…Introduction Sentinel lymph node biopsy (SLNB) is important for staging in patients with primary cutaneous melanoma. Did having previously undergone SLNB also…”
Get full text

ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? by Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., van Akkooi, Alexander C. J.

Get full text